98%
921
2 minutes
20
Several bacterial vaginosis (BV)-associated bacteria have been associated with elevated risk of HIV acquisition, however susceptibility of these bacteria to antibiotics is poorly understood. Vaginal samples were collected from 22 persons daily for two weeks following BV diagnosis. Metronidazole treatment was prescribed for 5-7 days. Changes in bacterial concentrations were measured with taxon-specific 16S rRNA gene quantitative PCR (qPCR) assays. A culture-based antimicrobial assay confirmed presence of antibiotics in vaginal swab samples. Bacterial DNA concentrations decreased during antibiotic administration for all thirteen bacterial taxa tested. Comparison of bacterial DNA concentrations in samples before administration of antibiotics to samples taken on the last day of antimicrobial assay-confirmed antibiotic presence showed a 2.3-4.5 log10-fold decrease across all taxa. Concentrations were frequently reduced to the qPCR assay's limit of detection, suggesting eradication of bacteria. Mean clearance time varied across taxa (1.2-8.6 days), with several bacteria (e.g., , spp., -like sp.) taking >7 days to suppress. Metronidazole reduces quantities of bacterial taxa associated with increased HIV acquisition risk. Eradication of high-risk vaginal bacteria using metronidazole is one promising avenue for reducing HIV acquisition risk. A 5-7-day treatment course may not be sufficient to suppress all bacteria.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11042432 | PMC |
http://dx.doi.org/10.21203/rs.3.rs-4219764/v1 | DOI Listing |
PLoS Med
September 2025
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Background: Oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence. For men who have sex with men, a dosing study in the United States (US) population defined clinically meaningful tenofovir diphosphate (TFV-DP) thresholds in dried blood spots (DBS) based on the rounded 25th percentile for 2, 4, and 7 doses/week as 350, 700, and 1,250 fmol/punch. However, divergent efficacy results in the first generation randomized clinical trials of F/TDF PrEP among African women led to several hypotheses to question whether the pharmacology and adherence requirement for oral F/TDF PrEP may be different in cisgender women compared to what is already established for men.
View Article and Find Full Text PDFmBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDFDrug Alcohol Depend
August 2025
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Objective: To estimate the association between medical and legal gender affirmation with problematic substance use among transfeminine adults.
Methods: Data from a longitudinal cohort (The LITE Study) were analyzed (n = 1186). Participants were enrolled between March 2018 and August 2020 and followed for 2 years.
Analyst
September 2025
Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
Curable sexually transmitted infections (STIs) caused by the bacteria (CT) and (NG) are widespread globally. These infections are particularly dangerous for female patients, causing pelvic inflammatory disease, infertility, and increased risk of HIV acquisition. Vaginal self-swab sampling can improve access to STI screening but is still subject to treatment delays due to centralized processing.
View Article and Find Full Text PDFFront Public Health
September 2025
School of Public Health, University of Rwanda, Kigali, Rwanda.
Background: Female sex workers (FSWs) in sub-Saharan Africa bear a disproportionate burden of HIV acquisition. While pre-exposure prophylaxis (PrEP) is increasingly accessible in the region, limited data exist on FSWs awareness of and willingness to use PrEP. This study aimed to assess PrEP awareness and willingness to use it, along with associated factors, among FSWs in Kigali, Rwanda.
View Article and Find Full Text PDF